222 related articles for article (PubMed ID: 30260084)
1. Dosing recommendations based on population pharmacokinetics of tacrolimus in Mexican adult patients with kidney transplant.
Reséndiz-Galván JE; Medellín-Garibay SE; Milán-Segovia RDC; Niño-Moreno PDC; Isordia-Segovia J; Romano-Moreno S
Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):303-311. PubMed ID: 30260084
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.
Zhang HJ; Li DY; Zhu HJ; Fang Y; Liu TS
J Clin Pharm Ther; 2017 Aug; 42(4):425-432. PubMed ID: 28401703
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
Jacobo-Cabral CO; García-Roca P; Romero-Tejeda EM; Reyes H; Medeiros M; Castañeda-Hernández G; Trocóniz IF
Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients.
Zhao W; Fakhoury M; Baudouin V; Storme T; Maisin A; Deschênes G; Jacqz-Aigrain E
Eur J Clin Pharmacol; 2013 Feb; 69(2):189-95. PubMed ID: 22706623
[TBL] [Abstract][Full Text] [Related]
8. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation.
Han N; Ha S; Yun HY; Kim MG; Min SI; Ha J; Lee JI; Oh JM; Kim IW
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):400-6. PubMed ID: 24238261
[TBL] [Abstract][Full Text] [Related]
10. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.
Andrews LM; Hesselink DA; van Schaik RHN; van Gelder T; de Fijter JW; Lloberas N; Elens L; Moes DJAR; de Winter BCM
Br J Clin Pharmacol; 2019 Mar; 85(3):601-615. PubMed ID: 30552703
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
Zhao W; Elie V; Roussey G; Brochard K; Niaudet P; Leroy V; Loirat C; Cochat P; Cloarec S; André JL; Garaix F; Bensman A; Fakhoury M; Jacqz-Aigrain E
Clin Pharmacol Ther; 2009 Dec; 86(6):609-18. PubMed ID: 19865079
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
[TBL] [Abstract][Full Text] [Related]
13. Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant.
Hannachi I; Ben Fredj N; Chadli Z; Ben Fadhel N; Ben Romdhane H; Touitou Y; Boughattas NA; Chaabane A; Aouam K
Toxicol Appl Pharmacol; 2020 Jun; 396():115000. PubMed ID: 32275916
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.
Moes DJ; van der Bent SA; Swen JJ; van der Straaten T; Inderson A; Olofsen E; Verspaget HW; Guchelaar HJ; den Hartigh J; van Hoek B
Eur J Clin Pharmacol; 2016 Feb; 72(2):163-74. PubMed ID: 26521259
[TBL] [Abstract][Full Text] [Related]
15. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.
Andrews LM; Hesselink DA; van Gelder T; Koch BCP; Cornelissen EAM; Brüggemann RJM; van Schaik RHN; de Wildt SN; Cransberg K; de Winter BCM
Clin Pharmacokinet; 2018 Apr; 57(4):475-489. PubMed ID: 28681225
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.
Benkali K; Prémaud A; Picard N; Rérolle JP; Toupance O; Hoizey G; Turcant A; Villemain F; Le Meur Y; Marquet P; Rousseau A
Clin Pharmacokinet; 2009; 48(12):805-16. PubMed ID: 19902988
[TBL] [Abstract][Full Text] [Related]
17. Effect of drug combination on tacrolimus target dose in renal transplant patients with different
Zhang SF; Tang BH; Wei AH; Du Y; Guan ZW; Li Y
Xenobiotica; 2022 Mar; 52(3):312-321. PubMed ID: 35395919
[TBL] [Abstract][Full Text] [Related]
18. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients.
Spierings N; Holt DW; MacPhee IA
Ther Drug Monit; 2013 Jun; 35(3):328-31. PubMed ID: 23666583
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen.
Reséndiz-Galván JE; Romano-Aguilar M; Medellín-Garibay SE; Milán-Segovia RDC; Niño-Moreno PDC; Jung-Cook H; Chevaile-Ramos JA; Romano-Moreno S
Eur J Pharm Sci; 2020 Jul; 150():105370. PubMed ID: 32387086
[TBL] [Abstract][Full Text] [Related]
20. A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.
Andreu F; Colom H; Elens L; van Gelder T; van Schaik RHN; Hesselink DA; Bestard O; Torras J; Cruzado JM; Grinyó JM; Lloberas N
Clin Pharmacokinet; 2017 Aug; 56(8):963-975. PubMed ID: 28050888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
